3plk Citations

Correlating structure and ligand affinity in drug discovery: a cautionary tale involving second shell residues.

Abstract

A high-resolution crystallographic structure determination of a protein-ligand complex is generally accepted as the 'gold standard' for structure-based drug design, yet the relationship between structure and affinity is neither obvious nor straightforward. Here we analyze the interactions of a series of serine proteinase inhibitors with trypsin variants onto which the ligand-binding site of factor Xa has been grafted. Despite conservative mutations of only two residues not immediately in contact with ligands (second shell residues), significant differences in the affinity profiles of the variants are observed. Structural analyses demonstrate that these are due to multiple effects, including differences in the structure of the binding site, differences in target flexibility and differences in inhibitor binding modes. The data presented here highlight the myriad competing microscopic processes that contribute to protein-ligand interactions and emphasize the difficulties in predicting affinity from structure.

Articles citing this publication (5)

  1. Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses. Braun NJ, Quek JP, Huber S, Kouretova J, Rogge D, Lang-Henkel H, Cheong EZK, Chew BLA, Heine A, Luo D, Steinmetzer T. ChemMedChem 15 1439-1452 (2020)
  2. Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine Proteases. Furtmann N, Häußler D, Scheidt T, Stirnberg M, Steinmetzer T, Bajorath J, Gütschow M. Chemistry 22 610-625 (2016)
  3. A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein. Schnapp G, Hoevels Y, Bakker RA, Schreiner P, Klein T, Nar H. ChemMedChem 16 630-639 (2021)
  4. Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors. Maiwald A, Hammami M, Wagner S, Heine A, Klebe G, Steinmetzer T. J Enzyme Inhib Med Chem 31 89-97 (2016)
  5. Characterization of the Interaction Between Pancreatic Trypsin and an Enteric Copolymer as a Tool for Several Biotechnological Applications. Braia MJ, Loureiro DB, Tubio G, Romanini D. Colloids Surf B Biointerfaces 136 1217-1223 (2015)